Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients-Reference-Cited by-同舟云学术

Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients

Published:2018-01 Issue:1 Volume:89 Page:60-66
ISSN:0923-1811
Container-title:Journal of Dermatological Science
language:en
Short-container-title:Journal of Dermatological Science

Author:

Fujisawa Yasuhiro,Yoshino Koji,Otsuka Atsushi,Funakoshi Takeru,Uchi Hiroshi,Fujimura Taku,Matsushita Shigeto,Hata Hiroo,Okuhira Hisako,Tanaka Ryota,Nagai Kojiro,Ishida Yoshihiro,Nakamura Yoshio,Furudate Sadanori,Yamamura Kentaro,Imafuku Keisuke,Yamamoto Yuki

Publisher

Elsevier BV

Subject

Dermatology,Molecular Biology,Biochemistry

Reference38 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010

2. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy;O'Reilly;Exp. Rev. Anticancer Ther.,2017

3. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations;Baksh;Semin. Oncol.,2015

4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N. Engl. J. Med.,2015

5. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N. Engl. J. Med.,2012

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous Adverse Reactions and Survival Outcomes of Advanced Melanoma Treated with Immune Checkpoint Inhibitors in an Academic Medical Centre in Singapore;Diagnostics;2024-07-25

2. Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective;Cancers;2023-12-24

3. Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy - a review;Biomolecules and Biomedicine;2023-08-29

4. Current Status in Rechallenge of Immunotherapy;International Journal of Biological Sciences;2023

5. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer;Journal for ImmunoTherapy of Cancer;2023-01